A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY

Authors :: Michael S. Weiss
Ian W. Flinn
Anthony R. Mato
James A. Reeves
Nicole Lamanna
E. Luning Prak
Colleen Dorsey
Stephen J. Schuster
N.M. LaRatta
Frederick Lansigan
John M. Pagel
Gustavo Fonseca
Hari P. Miskin
Bruce D. Cheson
Paul M. Barr
Suman Kambhampati
Hanna Weissbrot
Jakub Svoboda
Patricia Y. Tsao
Peter Sportelli
Jeffrey J. Pu
Alan P Skarbnik
Andrea Sitlinger
Dana Paskalis
Danielle M. Brander
Jaqueline C. Barrientos
Source :: Hematological Oncology. 37:88-89
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
biology
business.industry
Chronic lymphocytic leukemia
Phases of clinical research
Hematology
General Medicine
medicine.disease
Internal medicine
medicine
biology.protein
Bruton's tyrosine kinase
In patient
business
PI3K/AKT/mTOR pathway

Tools